CANbridge Pharmaceuticals (1228) H1 2025 earnings summary

Executive summary

• Achieved key milestones in rare disease drug pipeline, including new product approvals, expanded insurance coverage in China, and strategic cooperation with Baheal Medical, securing RMB50 million engagement fee and HK$100 million equity investment.

• Three rare disease products passed China's NHSA innovative drug catalog review, supporting future reimbursement and market access.

• Streamlined operations, reduced workforce to 45, and prioritized key rare disease programs amid challenging biotech funding environment.

• Commercial launches of Hunterase® and Livmarli® accelerated patient identification and insurance coverage.

• Gaurunning® received marketing approval for Gaucher disease in China, marking a significant product milestone.

Financial highlights

• Revenue dropped 50.3% year-over-year to RMB22.2 million, mainly due to cessation of Nerlynx® sales in Taiwan; excluding this, revenue declined 6.9%.

• Gross profit was RMB15.4 million with a margin of 69.3%, up from 65.7% last year.

• Other income and gains surged to RMB104.1 million, driven by a RMB101.0 million gain from US lease termination.

• R&D expenses fell 89.6% to RMB18.0 million after Gaurunning NDA approval; admin and selling expenses also decreased significantly.

• Reported profit of RMB59.2 million (vs. RMB247.3 million loss prior year), mainly from non-recurring items; adjusted loss narrowed to RMB37.4 million.

• Cash and bank balances at RMB2.0 million, with net current liabilities of RMB462.7 million and net liabilities of RMB409.1 million as of June 30, 2025.

Outlook and guidance

• Optimistic for H2 2025, focusing on pipeline streamlining, capital efficiency, and leveraging Baheal Medical partnership for growth.

• Plans to accelerate commercialization of Gaurunning and improve profitability of Hunterase® and Livmarli®.